Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Krippl Peter |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Valentin, A; Wichmann, H; Neugebauer, K; Krippl, P; Krause, R; Valentin, T
Nomen est omen: acute haemolytic anaemia in a patient with persistent Staphylococcus haemolyticus bacteraemia associated with
intravascular foreign material
http://www.oeginfekt.at/download/13_oeik_programm_2019_v5.pdf. 2019; -13. Österreichischer Infektionskongress ; MAR 27-30, 2019; Saalfelden am Steinernen Meer.
[Poster]
FullText
Scheithauer, W; Prager, G; Greil, R; Mlineritsch, B; Schaberl-Moser, R; Gerger, A; Langle, F; Viragos-Toth, I; Andel, J; Pichler, A; Pecherstorfer, M; Kretschmer, A; Seebacher, A; Jagdt, B; Eisterer, W; Krippl, P
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.41
[Poster]
Web of Science
FullText
FullText_MUG
Zweiker, D; Rosch, K; Schumacher, M; Stepan, V; Krippl, P; Bauer, N; Heine, M; Reicht, G; Zweiker, G; Watzinger, N
Benefit and Risk Assessment for the Initiation of oral Anticoagulation in non-valvular Atrial Fibrillation: The Self-assessment by the Patient differs from the individual Risk Assessment by means of CHA2DS2-VASc and HASBLED Scores
WIEN KLIN WOCHENSCHR. 2016; 128: S391-S392.
[Poster]
Web of Science
Zweiker, D; Rosch, K; Schumacher, M; Stepan, V; Krippl, P; Heine, M; Reicht, G; Zweiker, G; Watzinger, N
Benefit and Risk Assessment in Initiation of oral Anticoagulant in non valvularem Atrial Fibrillation: A Comparison between Self Assessment by the Patient and an individual Risk Assessment by CHA2DS2VASc and HAS-BLED Scores
WIEN KLIN WOCHENSCHR. 2016; 128: S299-S300.
[Poster]
Web of Science
Schmidt, S; Wolfler, A; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Wiesholzer, M; Woll, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G
Tyrosin kinase inhibitors usage and response analysis in the Austrian CML registry cohort
ONCOL RES TREAT. 2015; 38: 133-133.
[Poster]
Web of Science
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome
BLOOD. 2014; 124(21):
Doi: 10.1182/blood.V124.21.2284.2284
Web of Science
FullText
FullText_MUG
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry
BLOOD. 2014; 124(21):
Web of Science
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry
BLOOD. 2014; 124(21):
Web of Science
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes
BLOOD. 2014; 124(21):
Web of Science
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstoker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry
BLOOD. 2014; 124(21):
Doi: 10.1182/blood.V124.21.3681.3681
Web of Science
FullText
FullText_MUG
Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Kielhauser, S; Gerger, A; Absenger, G; Glehr, M; Szkandera, J; Samonigg, H; Krippl, P; Renner, W
Association of a common single nucleotide polymorphism in the TRAIL-R1 gene with relapse-free survival in rectal cancer patients.
Annals of Oncology. 2013; 24, Suppl. 4: iv51-iv52.-ESMO 15th World Congress on Gastrointestinal Cancer; JULY, 3-6, 2013; Barcelona, SPAIN. (ISBN: 0923-7534 )
[Poster]
Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Gerger, A; Kielhauser, S; Absenger, G; Szkandera, J; Samonigg, H; Krippl, P; Renner, W;
COMMON VEGF GENE POLYMORPHISMS ARE NOT ASSOCIATED WITH RELAPSE-FREE SURVIVAL IN COLORECTAL CANCER PATIENTS.
ANN ONCOL. 2012; 23: 86-87.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Gerger, A; Kielhauser, S; Thurner, E-M; Absenger, G; Szkandera, J; Samonigg, H; Glehr, M; Krippl, P; Renner, W
Genetic variants of UGT1A4 and their impact on relapse-free survival in Tamoxifen treated breast cancer patients.
Onkologie. 2012; 35(S 6):64-64.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OCT 19-23, 2012; Stuttgart, GERMANY.
[Poster]
Web of Science
Rossmann, C; Balic, M; Krippl, P;
COMPARISON OF OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER PATIENTS - DAILY PRACTICE VERSUS RANDOMIZED TRIALS.
ANN ONCOL. 2012; 23: 95-95.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Bitsche, S; Absenger, G; Samonigg, H; Krippl, P; Renner, W
RELAPSE-FREE SURVIVAL IN COLORECTAL CANCER PATIENTS IS NOT ASSOCIATED WITH SINGLE NUCLEOTIDE POLYMORPHISMS IN INTEGRIN RECEPTOR SUBUNITS
ANN ONCOL. 2011; 22: v109-v109.-ESMO 13th World Congress on Gastrointestinal Cancer ; JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Szkandera, J; Absenger, G; Samonigg, H; Krippl, P; Renner, W
A COMMON HEREDITARY SINGLE NUCLEOTIDE POLYMORPHISM IN THE IN THE GENE OF DEATH RECEPTOR 4 (TNFRSF10A) AND ITS IMPACT ON OVERALL SURVIVAL IN RECTAL CANCER PATIENTS
ANN ONCOL. . 2011; 22: v129-v129.-ESMO 13th World Congress on Gastrointestinal Cancer; JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Szkandera, J; Absenger, G; Samonigg, H; Krippl, P; Renner, W
Common single nucleotide polymorphisms in the genes of integrin alpha-2 and beta-3 subunits are not associated with overall survival in rectal cancer patients
ONKOLOGIE. 2011; 34: 245-246.-Gemeinsame Jahrestagung 2011 der DGHO, ÖGHO, SGMO und SGH+SSH; SEP 30-OCT 4, 2011; Basel, SWITZERLAND.
[Poster]
Web of Science
Clar, H; Krippl, P; Renner, W; Langsenlehner, U; Leithner, A; Gruber, G; Hofmann, G; Yazdani-Biuki, B; Langsenlehner, T; Windhager, R
Risk profiling for bone metastasis and breast cancer: the influence of the 1498 C/T polymorphism of the vascular endothelial growth factor (VEGF).
Abstract book of the 22nd EMSOS, 7.O.03.2009; 210--22nd EMSOS-Meeting; MAY 13-16, 2009; Stuttgart, GERMANY.
[Oral Communication]
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Samonigg, H; Clar, H; Krippl, P; Renner, W
Association of a common-670 A > G polymorphism in the gene of TNFRSF6 (FAS) with overall survival in colorectal cancer patients
ANN ONCOL. 2008; 19(S 6):68-68.
[Oral Communication]
Web of Science
Hofmann, G; Gerger, A; Weitzer, W; Eder, T; Fürst, F; Renner, W; Samonigg, H; Krippl, P; Langsenlehner, U
Association of common integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk.
Supplement 121; 157(25):18-18.-Frühjahrstagung 2007 der Österreichischen Gesellschaft für Hämatologie und Onkologie; April 12-14; 2007; Vienna, Austria.
[Poster]
Hofmann, G; Gerger, A; Weitzer, W; Langsenlehner, T; Fuerst, F; Renner, W; Samonigg, H; Krippl, P; Langsenlehner, U
The ITGA2 807C > T polymorphism is associated with reduced colorectal cancer susceptibility
ANN ONCOL. 2007; 18: VII38-VII38.-2007 World Congress on Gastrointestinal Cancer; JUN 27-30, 2007; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Krippl, P; Eder, T; Fürst, F; Gerger, A; Renner, W; Weitzer, W; Samonigg, H; Langsenlehner, U
The hereditary 936 C/T polymorphism in the vascular endothelial growth factor gene is not associated with colorectal cancer susceptibility.
Supplement 121; 157(25):17-17.-Frühjahrstagung 2007 der Österreichischen Gesellschaft für Hämatologie und Onkologie; April 12-14, 2007; Vienna, Austria.
[Poster]
Langsenlehner, T; Langsenlehner, U; Hofmann, G; Krippl, P; Mayer, R; Kapp, KS;
A common polymorphism in the gene of cyclooxygenase-2 (PTGS2 8473T>C) and its association with prostate cancer risk: a population-based study.
Supplement 121; 157(25):21-21.-Frühjahrstagung 2007 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APRIL 12-14, 2007; Vienna, AUSTRIA .
[Poster]
Eder, T; Langsenlehner, U; Weitzer, W; Krippl, P; Mayer, R; Kapp, KS
Interleukin-10 promoter polymorphism and prostate cancer risk
ONKOLOGIE; 29(S3):-Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; NOV 4-7, 2006; Leipzig, GERMANY. (ISBN: 3-8055-8214-5 )
[Oral Communication]
Gerger, A; Horn, M; Samonigg, H; Langsenlehner, U; Krippl, P; Kerl, H; Smolle, J
Diagnostic virtual histopathology of untreated fresh specimens from squamous cell carcinoma using confocal laser-scanning microscopy
J INVEST DERMATOL. 126: 114-114.-European Society of Dermatological Research; Sep, 2006; Paris, France.
[Oral Communication]
Web of Science
Gerger, A; Kerl, H; Samonigg, H; Langsenlehner, U; Krippl, P; Smolle, J
Sensitivity and specificity of confocal laser scanning microscopy for in vivo diagnosis of malignant skin tumors
J INVEST DERMATOL. 126: 114-114.-European Society of Dermatological Research; Sep, 2006; Paris, France.
[Poster]
Web of Science
Langsenlehner, U; Eder, T; Renner, W; Gerger, A; Hofmann, G; Samonigg, H; Krippl, P
The cyclooxygenase-2 (PTGS2) 8473T > C polymorphism increases breast cancer risk.
BREAST CANCER RES TREAT. 2006; 100: S251-S252.-29th Annual San Antonio Breast Cancer Symposium; DEC 14-17, 2006; San Antonio, USA.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, U; Renner, W; Greimel, A; Samonigg, H; Krippl, P
Breast cancer metastasis-free survival and its association to a common hereditary gene polymorphism of cyclin D1
BREAST CANCER RES TREAT. 94: S-78-S-79.
Web of Science
Langsenlehner, U; Eder, T; Weitzer, W; Samonigg, H; Krippl, P
The most common integrin ITGA2 haplotype (807C_1648G, wildtype) is associated with decreased breast cancer risk
BREAST CANCER RES TREAT 2005 94: -.
Web of Science
Langsenlehner, U; Krippl, P; Eder, T; Weitzer, W; Samonigg, H
Interleukin-10 TCATA haplotype is associated with decreased breast cancer risk
ANN ONCOL 2005 16: 271-271.
Web of Science
Krippl, P; Langsenlehner, U; Eder, T; Samonigg, H
The 5A/6A polymorphism of the stromelysin I gene promotor and breast cancer
BRIT J CANCER 2004 91: S25-S25.
Web of Science
Krippl, P; Langsenlehner, U; Samonigg, H
The 825C > T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer
BRIT J CANCER 2004 91: S56-S56.
Web of Science
Langsenlehner, U; Krippl, P; Eder, T; Samonigg, H
The SULT1A1 213H variant is associated with the presence of lymph node metastases in breast cancer patients
BRIT J CANCER 2004 91: S26-S26.
Web of Science
Langsenlehner, U; Krippl, P; Samonigg, H
The 677C > T polymorphism of methylenetetrahydro folate reductase gene and susceptibility to breast cancer
BRIT J CANCER 2004 91: S26-S26.
Web of Science
Langsenlehner, U; Samonigg, H; Krippl, P
The-1377G > A polymorphism in the FAS promoter region is associated with increased breast cancer susceptibility.
BREAST CANCER RES TREAT 2004 88: S72-S72.
Web of Science
Langsenlehner, U; Samonigg, H; Krippl, P
Vascular endothelial growth factor gene polymorphism decreases the risk for breast cancer metastasis.
BREAST CANCER RES TREAT 2004 88: S144-S145.
Web of Science
Leithner, A; Gapp, M; Leithner, K; Radl, R; Krippl, P; Beham, A; Windhager, R
Die Bedeutung von Resektionsgrenzen bei Extra-Abdominellen Aggressiven Fibromatosen
Proceedings of the 52. Jahrestagung der Vereinigung Süddeutscher Orthopäden2004; 207--52. Jahrestagung der Vereinigung Süddeutscher Orthopäden; May 2, 2004; Baden-Baden, GERMANY.
[Oral Communication]
Krippl, P; Langsenlehner, U; Renner, W; Samonigg, H
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk.
BREAST CANCER RES TREAT 2003 82: S140-S140.
Web of Science
Schippinger, W; Bauernhofer, T; Regitnig, P; Ploner, F; Krippl, P; Hofmann, G; Lax, S; Carney, W; Neumann, R; Wernecke, KD; Samonigg, H
Serum HER-2/neu dynamics in metastatic breast cancer as an independent prognostic factor.
BREAST CANCER RES TREAT 2003 82: S123-S123.
Web of Science
Schippinger, W; Bauernhofer, T; Ploner, F; Hofmann, G; Krippl, P; Neumann, R; Wernecke, KD; Samonigg, H
Serum HER-2/neu levels correlate with time to progression in therapy of metastatic breast cancer.
BREAST CANCER RES TREAT 2002 76: S104-S104.
Web of Science